NYSE: $GSK
Philadelphia, PA — October 19 2026 — GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite…
Source: Read More